检索结果-内蒙古大学图书馆

NAVAL ENGINEERS JOURNAL 1980年第6期92卷 35-42页

作者： CAMPBELL, JS THE AUTHOR was born in Porterville. Calif. in 1928 and joined the U.S. Nary in 1945 in the “Aviation Midshipman” Program. He received his designation as a Naval Aviator in 1950 and flew combat missions in Korea while still a Midshipman followed by participation in various operational and training squadrons until 1958 when he completed the Naval Test Pilot School Program. After a tour as an Engineering Test Pilot. he attended the Naval Postgraduate School Monterey. Calif. and was then assigned to the Fleet Computer Programming Center as a part of the NTDS development. Later he had operational tours as CIC Officer in the USS Enterprise and as AAW Officer on the Staff of Commander Task Force SEVENTY-SEVEN in Vietnam. During an interceding tour of duty he was the Program Manager for the TACDEW Training Facilities at San Diego Calif: and Dam Neck Va. After completing his active duty in the U.S. Navy Mr. Campbell joined Logicon Inc. and during the six years with the Tactical and Training Systems Division held various positions including Project Manager Department Head Assistant Director and Division Director prior to leaving in 1976 to join the Assistant Secretary of the Nary for R&D as Special Assistant for Weapons Systems Integration. In 1978 he joined the Staff at the Naval Ocean Systems Center as Associate Director for Command Control and Communications and Acting Head of the C3I Systems Department where he is charged with the development and operation of the C3Systems Integration Test and Evaluation Laboratory.

The increasingly important role of land-based test sites (LBTSs) in military command, control, and communications (C 3 ) is discussed, with particular reference to system integration, R&D, and testing. The LBTS at the Naval Ocean Systems Center (NOSC), San Diego, is described in detail, and lessons learned from the operation of the and other LBTSe are considered in terms of both their tactical and strategic implications.

关键词：

来源：评论

学校读者我要写书评

暂无评论

VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up

引用

Annals of Oncology 2022年第9期33卷 986-987页

作者： S. Loibl J. Jassem A. Sonnenblick D. Parlier E. Winer J. Bergh R.D. Gelber E. Restuccia Y-H. Im C. Huang F. Dalenc I. Calvo M. Procter C. Caballero E. Clark H.L. Gomez Moreno J. Bliss G. Viale J. Bines M. Piccart Medicine and Research Dept. German Breast Group (GBG) Forschungs GmbH Neu-Isenburg Germany Oncology & Radiotherapy Medical University of Gdansk Gdansk Poland Oncology Department Tel Aviv Sourasky Medical Center-(Ichilov) Tel Aviv Israel Clinical Trials Support Unit Institut Jules Bordet Brussels Belgium Yale Cancer Center Yale University School of Medicine - Yale Cancer Center New Haven CT USA Department of Oncology-Pathology Karolinska Institutet and Breast Cancer Centre Cancer Theme Karolinska University Hospital Stockholm Sweden Biostatistics Dana Farber Cancer Institute Boston MA USA Product Development Oncology F. Hoffmann-La Roche Ltd Basel Switzerland Medicine Dept. Hematology/Medical Oncology Division Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine Seoul Republic of Korea Surgery Dept. NTUH - National Taiwan University Hospital Taipei Taiwan Oncologie 1A Institut Universitaire du Cancer Toulouse - Oncopole Toulouse France Breast Cancer Unit MD Anderson Cancer Center Madrid Madrid Spain Statistics and Programming Frontier Science Scotland Kincraig UK Medical Department Breast International Group (BIG) - AISBL Brussels Belgium Data Sciences - Data & Statistical Sciences (DSS) Roche Products Limited Welwyn Garden City UK Medicine Department INEN - Instituto Nacional de Enfermedades Neoplasicas Lima Peru Clinical Trials and Statistics Unit ICR - Institute of Cancer Research London UK Department of Oncology Università degli Studi di Milano Milan Italy Medical Oncology Department Instituto Nacional de Cancer - Research Center Rio de Janeiro Brazil Institut Jules Bordet Brussels Belgium

来源：评论

学校读者我要写书评

暂无评论

ROLE OF SIMULATION IN RAPID PROTOTYPING FOR CONCEPT development

引用

NAVAL ENGINEERS JOURNAL 1991年第3期103卷 204-211页

作者： KING, JF BARTON, DE J. Fred King:is the manager of the Advanced Technology Department for Unisys in Reston Virginia. He earned his Ph.D. in mathematics from the University of Houston in 1977. He has been principal investigator of research projects in knowledge engineering pattern recognition and heuristic problem-solving. Efforts include the development of a multi-temporal multispectral classifier for identifying graincrops using LANDSAT satellite imagery data for NASA. Also as a member of the research team for a NCI study with Baylor College of Medicine and NASA he helped develop techniques for detection of carcinoma using multispectral microphotometer scans of lung tissue. He established and became technical director of the AI Laboratory for Ford Aerospace where he developed expert scheduling modeling and knowledge acquisition systems for NASA. Since joining Unisys in 1985 he has led the development of object-oriented programming environments blackboard architectures data fusion techniques using neural networks and intelligent data base systems. Douglas E. Barton:is manager of Logistics Information Systems for Unisys in Reston Virginia. He earned his B.A. degree in computer science from the College of William and Mary in 1978 and did postgraduate work in London as a Drapers Company scholar. Since joining Unisys in 1981 his work has concentrated on program management and software engineering of large scale data base management systems and design and implementation of knowledge-based systems in planning and logistics. As chairman of the Logistics Data Subcommittee of the National Security Industrial Association (NSIA) he led an industry initiative which examined concepts in knowledge-based systems in military logistics. His responsibilities also include evaluation development and tailoring of software engineering standards and procedures for data base and knowledge-based systems. He is currently program manager of the Navigation Information Management System which provides support to the Fleet Ballistic Missile Progr

A valuable technique during concept development is rapid prototyping of software for key design components. This approach is particularly useful when the optimum design approach is not readily apparent or several known alternatives need to be rapidly evaluated. A problem inherent in rapid prototyping is the lack of a "target system" with which to interface. Some alternatives are to develop test driver libraries, integrate the prototype with an existing working simulator, or build one for the specific problem. This paper presents a unique approach to concept development using rapid prototyping for concept development and scenario-based simulation for concept verification. The rapid prototyping environment, derived from artificial intelligence technology, is based on a blackboard architecture. The rapid prototype simulation capability is provided through an object-oriented modeling environment. It is shown how both simulation and blackboard technologies are used collectively to rapidly gain insight into a tenacious problem. A specific example will be discussed where this approach was used to evolve the logic of a mission controller for an autonomous underwater vehicle.

关键词： Military Engineering

来源：评论

学校读者我要写书评

暂无评论

AB1033 UNDERSTANDING THE IMPACT OF BELIMUMAB ON EARLY (≤2 YEARS) SYSTEMIC LUPUS ERYTHEMATOSUS IN ADULTS: BeEARLY, A PHASE 4, PROSPECTIVE, OPEN-LABEL STUDY

引用

Annals of the Rheumatic Diseases 2024年 83卷 1837-1837页

作者： M. Petri K. Costenbader M. Mosca S. Collingborn R.A. Levy C. O’shea H.A. Quasny John Hopkins University School of Medicine Division of Rheumatology Baltimore MD United States of America Brigham & Women’s Hospital Division of Rheumatology Inflammation and Immunity Boston MA United States of America University of Pisa Department of Clinical and Experimental Medicine Pisa Italy Veramed Statistics and Programming Frankfurt Germany GSK Global Medical Affairs Collegeville PA United States of America GSK Rheumatology Global Medical Affairs Dublin Ireland GSK Research & Development Durham NC United States of America

Background: Approximately 40% of patients with systemic lupus erythematosus (SLE) develop organ damage within the first 5 years of diagnosis due to uncontrolled disease activity and cumulative steroid exposure, resulting in a greater risk of early mortality. [1] Timely intervention with disease-modifying biologics such as belimumab (BEL) in the early stages of SLE might modify the disease course and prevent irreversible organ damage while avoiding the need for high-dose glucocorticoids (GCs) or immunosuppressants (IS). Previous studies suggested that BEL may have benefit when used earlier in the course of the disease, especially in patients with minimal or no organ damage at baseline who received BEL within 2 years of classification. [2,3] However, the use of BEL early in the treatment pathway has been limited in clinical practice, with the majority of BEL use following the failure of ≥2 IS. Objectives: Present the design of the BeEARLY (BEL in Early SLE) study, which will evaluate the efficacy and safety of BEL in adult SLE patients with early disease. Methods: In this Phase 4, prospective, open-label, single-arm, 3-year clinical study (GSK Study 219240), approximately 350 adult patients with active, autoantibody-positive, early SLE (≤2 years since diagnosis) with no organ damage and with inadequate response to initial standard therapy (ST; with/without conventional IS) will be enrolled. Key eligibility criteria are shown in Table 1 . Eligible participants will receive open-label BEL 200 mg/week subcutaneously as an add-on to their initial ST for 52 weeks (Part A), with a long-term extension of up to 104 weeks (end of study is the safety follow-up visit after Week 156; Part B). Key primary and secondary endpoints are shown in Table 2 . Participants will be required to taper the average oral GC (OGC; prednisone equivalent) dose from Week 12 to ≤7.5 mg/day by Week 26, and to ≤5 mg/day by Week 48 at the discretion of the investigator if they continue to maintain stabl

关键词：

来源：评论

学校读者我要写书评

暂无评论

Durability of alirocumab effect: Data from an open-label extension to the ODYSSEY program for patients with heterozygous familial hypercholesterolemia

引用

Annales d'Endocrinologie 2017年第4期78卷 301-301页

作者： M. Farnier G.K. Hovingh G. Langset R. Dufour M. Baccara-Dinet C. Din-Bell G. Manvelian J.R. Guyton Lipid clinic – Point Médical Dijon France Department of Vascular Medicine Academic Medical Center Amsterdam The Netherlands Lipid Clinic Oslo University Hospital Oslo Norway Institut de recherches cliniques de Montréal Université de Montréal Montréal QC Canada Clinical Development R&D Sanofi Montpellier France Biostatistics and Programming Sanofi Chilly-Mazarin France Regeneron Pharmaceuticals Tarrytown NY USA Duke University Medical Center Durham NC USA

Purpose To evaluate the overall durability of the effect of alirocumab in patients with heterozygous familial hypercholesterolemia (HeFH) using data from the ODYSSEY open-label extension (OLE) of four phase 3 trials (FHI, FHII, LONG-TERM, HIGH-FH) assessing long-term efficacy and safety for up to 40 months. Methods Patients received alirocumab 75 mg (FHI, FHII, LONG-TERM) or 150 mg (HIGH-FH) once every 2 weeks. From Week 12, dose adjustment of alirocumab was allowed as per investigator's clinical judgement. Results A total of 985 patients (mean age 54.4 years, 55.8% male) were included in OLE safety population. At OLE enrollment, 978 patients were receiving statins with 627 other lipid-lowering therapy. At the time of analysis, 938 patients had completed ≥ 1 year of treatment; 5.7% had discontinued treatment (2.2% due to adverse events). Of those who started OLE on 75 mg dose, 537/909 (59.1%) were maintained on that dose throughout. At Week 48 of OLE, the mean LDL-C was 79.7 mg/dL, a mean reduction of 46.9% compared with baseline levels of the parent studies. Other lipid changes included reductions at Week 48 in non-high density lipoprotein cholesterol (40.3%), total cholesterol (29.7%), lipoprotein(a) (25.6%), and apolipoprotein B (37.5%). Overall, 762/985 (77.4%) patients reported treatment-emergent adverse events during OLE (up to 73 weeks). Injection site reactions reported by 49 patients (5.0%) were mild and self-limited. Conclusion In this OLE study of patients with HeFH, alirocumab demonstrated a durable and robust treatment effect, yielding a 47% reduction in LDL-C at Week 48 compared with baseline levels.

关键词：

来源：评论

学校读者我要写书评

暂无评论

7 Phase 3 Trial of an Oral CXCR4 Antagonist, Mavorixafor, for Treatment of Patients With WHIM Syndrome: Preliminary Results From Ongoing Open-Label Extension Period of Continuous Mavorixafor Treatment

引用

Clinical Immunology 2024年 262卷 109949-109949页

作者： Tarrant, Teresa Badolato, Raffaele Donadieu, Jean Dubuc, Susan Hu, Yanping Jiang, Honghua Li, Sunny Steiner, Deborah Yan, Tina Arbet-Engels, Christophe Associate Professor of Medicine Rheumatology and Immunology/Division of Rheumatology and Immunology Department of Medicine Duke University Durham NC USA Full Professor of Pediatrics Chair of Pediatrics ASST Spedali Civili Brescia/Department of Clinical and Experimental Sciences University of Brescia & ASST Spedali Civili Brescia Italy Pediatric Physician/CHU Paris Est - Hôpital d’Enfants Armand-Trousseau Paris France Senior Director Pharmacovigilance & Risk Management/X4 Pharmaceuticals Boston MA USA Director Clinical Research/X4 Pharmaceuticals Boston MA USA Senior Director Biostatistics/X4 Pharmaceuticals Boston MA USA Senior Director Statistical Programming/X4 Pharmaceuticals Boston MA USA Vice President Clinical Development/X4 Pharmaceuticals Boston MA USA Director Statistical Programming/X4 Pharmaceuticals Boston MA USA Chief Medical Officer/X4 Pharmaceuticals Boston MA USA

来源：评论

学校读者我要写书评

暂无评论

Control of ship fouling in U.S. Navy

引用

Naval Engineers Journal 1967年第N 1期v 79卷 p77-85页

作者： Birnbaum, L.S. Bukzin, E.A. Saroyan, J.R. Leon S. Birnbaum holds a B.S. degree in Chemistry from City College of New York. He has completed graduate work in Chemistry at the University of Maryland and Temple University and in Technology and Management at American University. He has been with the Navy Department Washington since 1949 and is currently Head of the Coatings and Chemistry Branch of the Materials Development and Application Office of the Naval Ship Engineering Center. Responsibilities of this Branch include such items as coatings corrosion control techniques insulation chemical cleaning water treatment toxicology and detection and decontamination of biological and chemical warfare agents. Prior to this Mr. Birnbaum was employed in the Industrial Test Laboratory Philadelphia Naval Shipyard from 1938 to 1949. Work during this period included supervision of a section which inspected paints and allied materials and petroleum products to determine their suitability for Naval use and direction of research in fire retardant treatments. He is a member of the American Chemical Society Washington Paint Technical Group. National Association of Corrosion Engineers and the American Society of Naval Engineers. Mr. Bukzin is a research and development program manager in the Naval Ship Systems Command of the Department of the Navy in the fields of non-metallic materials fuels lubricants cold weather operations and several other areas. He is a graduate chemical engineer from New York University with additional training in naval architecture and management which culminated in his participation in the Senior Development Program at Cornell University during the summer of 1960. He has been employed by the Command and its predecessor for the past 2b years and has been in his present position of R&D planning and programming for the past six years. Prior to that his major technical responsibilities were in the field of elastomers and their applications. He received several awards and published a number of papers during those years. Mr. Bukzin is a me

Report on paints used on surface ships and submarines for protection against corrosion and prevention of fouling, and on work connected with development and evaluation of such coatings;experiences with "hot plastic", "cold plastic" and vinyl paints;hazards in use of vinyl paints and safety precautions;test techniques;new toxics (which are only kind so far satisfactory antifouling formulations) under test.

关键词： Ships

来源：评论

学校读者我要写书评

暂无评论

277MO SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2- metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study

引用

Annals of Oncology 2020年 31卷 S351-S351页

作者： S. Chandarlapaty A. Bardia S. Lord H. Linden V. Pelekanou N. Ternes J. Ming V. Boutet E. Boitier A. Gosselin J. Sang Lee W. Dos-Santos Bele A. Protopopov M. Celanovic A-L. Bauchet M. Campone Medicine Memorial Sloan Kettering Cancer Center New York NY USA Medical Oncology Massachusetts General Hospital Harvard Medical School Boston MA USA Department of Oncology University of Oxford Churchill Hospital Oxford UK Department of Medicine University of Washington Medical Center Seattle WA USA Clinical Precision Oncology-Tranlsational Medicine Early Development Sanofi Cambridge MA USA Biostatistics and Programming Sanofi Paris France Oncology Sanofi Bridgewater NJ USA TMED & Biomarkers & Clinical Bioanalyses Sanofi Paris France Precision Oncology Sanofi Cambridge MA USA Molecular Profiling Precision Oncology Sanofi Paris France Oncology-OMD Sanofi Cambridge MA USA Medical Oncology Institut de Cancérologie de l'Ouest Saint-Herblain France

来源：评论

学校读者我要写书评

暂无评论

Symposia lectures

引用

Journal of Biosciences 1999年第1期24卷 5-31页

作者： F. Parak A. Ostermann G. U. Nienhaus Nobuo Niimura William A. Eaton Stephen J. Hagen Eric R. Henry James Hofrichter Gouri Jas Lisa Lapidus Victor Muñoz Chih-chen Wang Abani Bhuyan Javant Udgaonkar Heinz Rüterians Derek N. Woolfson M. D. Finucane J. H. Lees M. J. Pandya G. Spooner M. Tuna Wilma K. Olson K. V. R. Chary E. Westhof I. G. Wool C. C. Correll V. I. Ivanov S. A. Bondarenko E. M. Zdobnov A. D. Beniaminov E. E. Minyat N. B. Ulyanov Dale B. Wigley Nobuo Shimamoto Takashi Kinebuchi Hiroyuki Kabata Osamu Kurosawa Masao Washizu Barbara Baird David Holowka H. Belrhali P. Nollert A. Royant J. P. Rosenbusch E. M. Landau E. Pebav-Peyroula Anil K. Lala Patrick R. D’Silva Daniela Pietrobon Paolo Pinton Paulo Magalhaes Anna Chiesa Marisa Brini Tullio Pozzan Rosario Rizzuto M. Montai Shu-Rong Wang José L. Carrascosa B. Bhattacharyya Ian A. Wilson Dinakar M. Salunke Kurt Drickamer Anne Imberty A. Surolia Louise N. Johnson Michal Neeman S. M. Prince K. McLuskey R. J. Cogdell K. McAuley N. W. Isaacs G. Venturoli F. Drepper J. C. Williams J. P. Allen X. Lin P. Mathis R. van Grondelle Wolfgang Junge T. Tsukihara K. Shinzawa-Itoh R. Nakashima E. Yamashita M. J. Fei N. Inoue T. Tomizaki C. Peters Libeu S. Yoshikawa Patrick Chaussepied Keiichi Namba Marie-France Carlier Fariza Ressacl Valerie Laurent Thomas Loisel Coumaran Egile Philippe Sansonetti Dominique Pantaloni Manju Bansal E. W. Knapp M. G. Ullmann A. Amadei B. L. de Groot M. A. Ceruso M. Paci H. J. C. Berendsen A. Di Nola V. Di Francesco P. J. Munson J. Garnier Sung-Hou Kim Jean-Michel Claverie Ian C. P. Smith P. T. Callaghan Bruce Cornell Ratna S. Phadke Kazuhiko Kinosita D. Goldfarb I. Qromov C. Shutter I. Pecht P. Manikandan R. Carmieli T. Shane David S. Moss Clare E. Sansom Jeremy K. Cockcroft Ian J. Tickle Huub C. P. Driessen J. Raul Grigera Ramen K. Poddar Charles R. Cantor Barry Robson Jean Garnier John Helliwell Sunney I. Chan Ronald Rock Physik-Department El7 Technische Universität München Garching Abteilung Biophysik Universität Ulm Ulm Advanced Science Research Center Japan Atomic Energy Research Institute Japan Laboratory of Chemical Physics NIDDK National Institutes of Health Bethesda USA National Lab of Biomacromolecules Institute of Biophysics Beijing China National Centre for Biological Sciences Bangalore Institute of Biophysical Chemistry University of Frankfurt Frankfurt/Main Germany Centre for Biomolecular Design and Drug Development University of Sussex UK Rutgers University Piscataway USA Department of Chemical Sciences Tata Institute of Fundamental Research Mumbai India IBMC-CNRS Strasbourg France Department of Biochemistry and Molecular Biology The University of Chicago Chicago USA Engelhardt Institute of Molecular Biology RAS Moscow Russia Sir William Dunn School of Pathology University of Oxford Oxford UK Structural Biology Center National Institute of Genetics Japan Faculty of Engineering Kyoto University Kyoto Advance Co. Tokyo Japan Department of Chemistry and Chemical Biology Cornell University Ithaca Institute de Biologie Structurale Joseph Fourier Grenoble Cedex 1 France Biomembrane Lab Department of Chemistry and Biotechnology CenterIndian Institute of Technology Bombay Powai Mumbai India Dept of Biomedical Sciences Univ. of Padova Italy Dept. Exp. Diagn. Med. Sect. Gen. Pathol Ferrara Italy Department of Biology University of California San Diego La Jolla USA Chinese Academy of Sciences Institute of Biophysics Beijing China Centra Nacional de Biotecnología CSIC. Campus de la Universidad Autónoma de Madrid Cantoblanco Spain Dept.of Biochemistry Bose Institute Calcutta-54 India The Scripps Research Institute La Jolla National Institute of Immunology New Delhi India Glycobiology Institute Department of Biochemistry University of Oxford Oxford UK Centre de Recherches sur les Macromolécules Végétales-CNRS Grenoble cedex 9 France Molecular Biophysics Uni

来源：评论

学校读者我要写书评

暂无评论

1411P Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)

引用

Annals of Oncology 2023年 34卷 S807-S807页

作者： G.K. Dy B.C. Cho J. Oliveira M.D. Isla Casado A. Blasco Cordellat M. Zemanova J. Roubec L. Vila Martinez L. Charbonnier C. Soufflet J. de Castro Carpeño Department of Medicine Roswell Park Comprehensive Cancer Center Buffalo NY USA Division of Medical Oncology Yonsei Cancer Center Yonsei University College of Medicine Seoul Republic of Korea Medical Oncology Service Early Phase Clinical Trial Unit-IPO Porto/RISE@CI-IPOP (Health Research Network Experimental Pathology and Therapeutics Group Research Center (CI-IPOP)/RISE@CI-IPOP (Health Research Network) Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Porto Portugal Medical Oncology Department Hospital Clínico Universitario Lozano Blesa Zaragoza Spain Medical Oncology Department Hospital General de Valencia Valencia Spain Department of Oncology First Faculty of Medicine Charles University and General University Hospital in Prague Prague Czech Republic Pneumooncology Nemocnice AGEL Ostrava-Vítkovice Ostrava-Vítkovice Czech Republic Oncology Department Consorci Corporació Sanitària Parc Taulí de Sabadell Sabadell Spain Biostatistics & Programming Sanofi Chilly-Mazarin France Clinical Development Sanofi Vitry-sur-Seine France Medical Oncology Service Hospital Universitario La Paz Madrid Spain

来源：评论

学校读者我要写书评

暂无评论

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案：

请选择收藏分类：

通借通还

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：